EU Crunch Time For Previously Rejected Lagevrio & Other New Drugs

 
• By Neena Brizmohun

MSD/Ridgeback Biotherapeutics’ COVID-19 treatment Lagevrio is among the products that are up for an opinion this week from the European Medicines Agency on whether they should be recommended for use across the EU.

Decisions are due on whether or not several new drugs should be approved for use in the EU • Source: Shutterstock

More from Europe

More from Geography